Alpha-Synuclein is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
This antibody was developed with support from The Michael J. Fox Foundation, in collaboration with the laboratory of Dr. Michael Schlossmacher (University of Ottawa).

This product is a recombinant monoclonal antibody, which offers several advantages including:

– High batch-to-batch consistency and reproducibility
– Improved sensitivity and specificity
– Long-term security of supply
– Animal-free batch production